Literature DB >> 10401710

Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.

G Guzzaloni1, G Grugni, F Morabito.   

Abstract

UNLABELLED: Hexarelin (HEX) is a synthetic hexapeptide with strong GH-stimulating activity. We evaluated GH response (expressed as maximum value after stimulus [Cmax] and as area under the curve [AUC]) to HEX at the doses of 1 microg/kg i.v. (HEX 1) and 2 microg/kg i.v. (HEX 2), in comparison with the responses to GHRH (1 microg/kg i.v.) + pyridostigmine (PD, 60 mg po) and to arginine (ARG, 0.5 mg/kg i.v.) + ethinylestradiol (EE, 1 mg/day po for 3 days before the stimulation), in 5 subjects with familial short stature (FSS), 11 with constitutional growth delay (CGD), 6 with GH neurosecretory dysfunction (NSD), and 5 with isolated growth hormone deficiency (GHD). Cmax and AUC after HEX 1 were 26.8+/-10.5 ng/ml and 1448+/-514 ng/min x ml in FSS, 23.6+/-14.4 ng/ml and 1146+/-750 ng/min x ml in CGD, 36.9+/-21.5 ng/ml and 2048+/-1288 ng/min x ml in NSD, 9.4+/-5.8 ng/ml and 498+/-200 ng/min x ml in GHD (Cmax and AUC in FSS and CGD, p<0.05 vs GHD). Cmax and AUC after HEX 2 were 37.7+/-16 ng/ml and 1979+/-888 ng/min x ml in FSS, 32.5+/-16.2 ng/ml and 1613+/-237 ng/min x ml in CGD, 39.7+/-20.7 ng/ml and 2366+/-1569 ng/min xml in NSD, 13.4+/-4.2 ng/ml and 645+/-293 ng/min x ml in GHD (Cmax in FSS, CGD and NSD p<0.01 vs GHD; AUC in NSD, p<05 vs GHD). Cmax and AUC after GHRH+/-PD were 46.6+/-8.8 ng/ml and 3294+/-1031 ng/min x ml in FSS, 25.9+/-11.2 ng/ml and 1464+/-735 ng/min x ml in CGD, 38.8+/-21.7 ng/ml and 2428+/-1399 ng/min x ml in NSD, 8.4+/-6.2 ng/ml and 685+/-572 ng/min x ml in GHD (Cmax and AUC in FSS, p<0.001 vs CGD and GHD; Cmax in CGD and NSD, p<0.001 vs GHD). Cmax and AUC after ARG+EE were 21.3+/-4.2 ng/ml and 1432+/-514 ng/min x ml in FSS, 14.8+/-10 ng/ml and 805+/-489 ng/min x ml in CGD, 22.2+/-12.8 ng/ml and 1199+/-309 ng/min x ml in NSD, 4.6+/-2.5 ng/ml and 247+/-191 ng/min x ml in GHD (Cmax and AUC in FSS, CGD and NSD, p<0.01 vs GHD). Specificity was 62% for HEX 1 and 75% for HEX 2, GHRH+PD and ARG+EE. From a diagnostic point of view, HEX 1 + HEX 2 was the association with the largest percentage of false positives (20% in FSS, 27% in CGD and 33% in NSD), HEX 1 +GHRH+PD resulted in 9% in CGD, while the combined use of HEX 1 or HEX 2 with GHRH+PD or ARG+EE and of GHRH+PD with ARG+EE did not show false positive responses. IN
CONCLUSION: I) the most effective dose of HEX was 2 microg/kg i.v.; 2) HEX did not show more specificity than GHRH+PD and ARG+EE; 3) the association of GHRH+PD with ARG+EE could yield the best results at lower costs, confirming these tests as first-line tools in evaluating GH secretion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10401710     DOI: 10.1007/BF03343574

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  51 in total

1.  A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.

Authors:  E Ghigo; E Imperiale; G M Boffano; E Mazza; J Bellone; E Arvat; M Procopio; S Goffi; A Barreca; P Chiabotto
Journal:  J Endocrinol Invest       Date:  1990-04       Impact factor: 4.256

2.  On a peptidomimetic growth hormone-releasing peptide.

Authors:  C Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

3.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids.

Authors:  S Loche; A Colao; M Cappa; J Bellone; G Aimaretti; G Farello; A Faedda; G Lombardi; R Deghenghi; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

5.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

6.  Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty.

Authors:  J Bellone; G Aimaretti; E Bartolotta; L Benso; B P Imbimbo; V Lenhaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

7.  Arginine-initiated release of human growth hormone. Factors modifying the response in normal man.

Authors:  T J Merimee; D Rabinowtitz; S E Fineberg
Journal:  N Engl J Med       Date:  1969-06-26       Impact factor: 91.245

8.  The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys.

Authors:  G Marin; H M Domené; K M Barnes; B J Blackwell; F G Cassorla; G B Cutler
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

Review 9.  Growth hormone secretagogues. Clinical experience and therapeutic potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

10.  Plasma growth hormone response to growth hormone-releasing hexapeptide (GH-RP-6) in children with short stature.

Authors:  M Pombo; J Barreiro; A Peñalva; F Mallo; F F Casanueva; C Dieguez
Journal:  Acta Paediatr       Date:  1995-08       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.